Cart
sales@molnova.com
SNS-032
CAS No. 345627-80-7
SNS-032 ( BMS-387032 )
Catalog No. M14183 CAS No. 345627-80-7
SNS-032 (BMS-387032)is a potent and selective inhibitor of CDK 2/7/9 with IC50 of 48 nM/62 nM/4 nM, respectively.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 39 | In Stock |
|
| 10MG | 55 | In Stock |
|
| 25MG | 79 | In Stock |
|
| 50MG | 120 | In Stock |
|
| 100MG | 203 | In Stock |
|
| 200MG | 300 | In Stock |
|
| 500MG | 503 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameSNS-032
-
NoteResearch use only, not for human use.
-
Brief DescriptionSNS-032 (BMS-387032)is a potent and selective inhibitor of CDK 2/7/9 with IC50 of 48 nM/62 nM/4 nM, respectively.
-
DescriptionSNS-032 (BMS-387032)is a potent and selective inhibitor of CDK 2/7/9 with IC50 of 48 nM/62 nM/4 nM, respectively; displays 10- and 20-fold selective over CDK1/cycB and CDK4/cycD (IC50=480 and 925 nM) respectively, and a panel of unrelated kinases, respectively; blocks the cell cycle via inhibition of CDKs 2 and 7, and transcription via inhibition of CDKs 7 and 9, has an A2780 cellular cytotoxicity assay IC50 of 95 nM; exhibits a efficacy profile in A2780 human ovarian carcinoma xenograft model.Blood Cancer,Phase 2 Discontinued
-
SynonymsBMS-387032
-
PathwayAngiogenesis
-
TargetCDK
-
RecptorCDK2/CyclinA;CDK2/CyclinE;CDK7/CyclinH;CDK9/CyclinT;GSK-3α
-
Research AreaCancer
-
IndicationBlood cancer
Chemical Information
-
CAS Number345627-80-7
-
Formula Weight380.53
-
Molecular FormulaC17H24N4O2S2
-
Purity>98% (HPLC)
-
Solubility10 mM in DMSO
-
SMILESCC(C)(C)C1=CN=C(CSC2=CN=C(NC(=O)C3CCNCC3)S2)O1 |t:4,6,10,12|
-
Chemical Name4-Piperidinecarboxamide, N-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Misra RN, et al. J Med Chem. 2004 Mar 25;47(7):1719-28.
2. Mukhopadhyay P, et al. Cancer Res. 2006 Feb 1;66(3):1758-66.
3. Chen R, et al. Blood. 2009 May 7;113(19):4637-45.
4. Heath EI, et al. Invest New Drugs. 2008 Feb;26(1):59-65.
2. Mukhopadhyay P, et al. Cancer Res. 2006 Feb 1;66(3):1758-66.
3. Chen R, et al. Blood. 2009 May 7;113(19):4637-45.
4. Heath EI, et al. Invest New Drugs. 2008 Feb;26(1):59-65.
molnova catalog
related products
-
CAN-508
CAN-508 is a potent, selective CDK9 inhibitor with IC50 of 0.35 uM (CDK9/cyclin T1), displays >35 fold selectivity over CDK1/2/4/7 (IC50=13.5-70 uM).
-
BAY-958
BAY-958 (BAY958, LDC526)is a potent, selective PTEFb/CDK9 inhibitor with IC50 of 5 nM against CDK9/CyclinT1.
-
(R)-CR8
(R)-CR8 is a potent and selective CDK inhibitor.A delayed systemic post-LFP administration at 3 hours of CR8--a potent second-generation cyclin-dependent kinase (CDK) inhibitor.
